INDIVIOR PHARMACEUTICALS INC (INDV) Fundamental Analysis & Valuation

NASDAQ:INDV • US45579U1097

Current stock price

30.47 USD
-0.18 (-0.59%)
At close:
30.47 USD
0 (0%)
After Hours:

This INDV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. INDV Profitability Analysis

1.1 Basic Checks

  • In the past year INDV was profitable.
  • INDV had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: INDV reported negative net income in multiple years.
  • In multiple years INDV reported negative operating cash flow during the last 5 years.
INDV Yearly Net Income VS EBIT VS OCF VS FCFINDV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

  • INDV's Return On Assets of 8.62% is amongst the best of the industry. INDV outperforms 89.58% of its industry peers.
  • The Return On Invested Capital of INDV (50.62%) is better than 100.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for INDV is significantly above the industry average of 13.06%.
  • The 3 year average ROIC (43.06%) for INDV is below the current ROIC(50.62%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROIC 50.62%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
INDV Yearly ROA, ROE, ROICINDV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300 400

1.3 Margins

  • INDV has a better Profit Margin (10.34%) than 84.90% of its industry peers.
  • In the last couple of years the Profit Margin of INDV has declined.
  • With an excellent Operating Margin value of 24.49%, INDV belongs to the best of the industry, outperforming 92.19% of the companies in the same industry.
  • INDV's Operating Margin has been stable in the last couple of years.
  • INDV has a better Gross Margin (85.51%) than 88.54% of its industry peers.
  • INDV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
INDV Yearly Profit, Operating, Gross MarginsINDV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. INDV Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), INDV is creating value.
  • There is no outstanding debt for INDV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INDV Yearly Shares OutstandingINDV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
INDV Yearly Total Debt VS Total AssetsINDV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • INDV has an Altman-Z score of 2.54. This is not the best score and indicates that INDV is in the grey zone with still only limited risk for bankruptcy at the moment.
  • INDV has a Altman-Z score of 2.54. This is in the better half of the industry: INDV outperforms 67.19% of its industry peers.
  • The Debt to FCF ratio of INDV is 2.68, which is a good value as it means it would take INDV, 2.68 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of INDV (2.68) is better than 91.67% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Altman-Z 2.54
ROIC/WACC5.28
WACC9.59%
INDV Yearly LT Debt VS Equity VS FCFINDV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 0.96 indicates that INDV may have some problems paying its short term obligations.
  • The Current ratio of INDV (0.96) is worse than 85.42% of its industry peers.
  • INDV has a Quick Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.79, INDV is doing worse than 82.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.79
INDV Yearly Current Assets VS Current LiabilitesINDV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. INDV Growth Analysis

3.1 Past

  • INDV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 459.09%, which is quite impressive.
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%

3.2 Future

  • Based on estimates for the next years, INDV will show a decrease in Earnings Per Share. The EPS will decrease by -3.07% on average per year.
  • Based on estimates for the next years, INDV will show a small growth in Revenue. The Revenue will grow by 0.79% on average per year.
EPS Next Y25.28%
EPS Next 2Y17.02%
EPS Next 3Y13.27%
EPS Next 5Y-3.07%
Revenue Next Year-2.63%
Revenue Next 2Y1.23%
Revenue Next 3Y2.83%
Revenue Next 5Y0.79%

3.3 Evolution

INDV Yearly Revenue VS EstimatesINDV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
INDV Yearly EPS VS EstimatesINDV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. INDV Valuation Analysis

4.1 Price/Earnings Ratio

  • INDV is valuated correctly with a Price/Earnings ratio of 12.39.
  • INDV's Price/Earnings ratio is rather cheap when compared to the industry. INDV is cheaper than 87.50% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.60. INDV is valued rather cheaply when compared to this.
  • Based on the Price/Forward Earnings ratio of 9.89, the valuation of INDV can be described as reasonable.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of INDV indicates a rather cheap valuation: INDV is cheaper than 88.02% of the companies listed in the same industry.
  • INDV is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.84, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.39
Fwd PE 9.89
INDV Price Earnings VS Forward Price EarningsINDV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, INDV is valued cheaply inside the industry as 84.90% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, INDV is valued cheaply inside the industry as 81.25% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 31.76
EV/EBITDA 11.71
INDV Per share dataINDV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of INDV may justify a higher PE ratio.
  • INDV's earnings are expected to grow with 13.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.49
PEG (5Y)N/A
EPS Next 2Y17.02%
EPS Next 3Y13.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INDV Dividend Analysis

5.1 Amount

  • INDV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INDV Fundamentals: All Metrics, Ratios and Statistics

INDIVIOR PHARMACEUTICALS INC

NASDAQ:INDV (4/2/2026, 8:00:02 PM)

After market: 30.47 0 (0%)

30.47

-0.18 (-0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)04-23
Inst Owners86.43%
Inst Owner Change-70.46%
Ins Owners3.62%
Ins Owner Change39.75%
Market Cap3.81B
Revenue(TTM)N/A
Net Income(TTM)122.00M
Analysts84.62
Price Target47.79 (56.84%)
Short Float %10.15%
Short Ratio4.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)81.89%
Min EPS beat(2)71.47%
Max EPS beat(2)92.31%
EPS beat(4)4
Avg EPS beat(4)70.49%
Min EPS beat(4)45.92%
Max EPS beat(4)92.31%
EPS beat(8)6
Avg EPS beat(8)12.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.31%
Min Revenue beat(2)17.53%
Max Revenue beat(2)21.1%
Revenue beat(4)4
Avg Revenue beat(4)14.97%
Min Revenue beat(4)8.6%
Max Revenue beat(4)21.1%
Revenue beat(8)5
Avg Revenue beat(8)7.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.82%
PT rev (3m)23.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.86%
EPS NY rev (3m)1.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1%
Valuation
Industry RankSector Rank
PE 12.39
Fwd PE 9.89
P/S 3.23
P/FCF 31.76
P/OCF 21.17
P/B N/A
P/tB N/A
EV/EBITDA 11.71
EPS(TTM)2.46
EY8.07%
EPS(NY)3.08
Fwd EY10.11%
FCF(TTM)0.96
FCFY3.15%
OCF(TTM)1.44
OCFY4.72%
SpS9.43
BVpS-1.66
TBVpS-1.67
PEG (NY)0.49
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 8.62%
ROE N/A
ROCE 64.08%
ROIC 50.62%
ROICexc 3805.17%
ROICexgc 5707.75%
OM 24.49%
PM (TTM) 10.34%
GM 85.51%
FCFM 10.17%
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)54.5%
ROCE(5y)38.6%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 2.68
Debt/EBITDA 0.97
Cap/Depr 230.77%
Cap/Sales 5.08%
Interest Coverage 250
Cash Conversion 57.14%
Profit Quality 98.36%
Current Ratio 0.96
Quick Ratio 0.79
Altman-Z 2.54
F-Score8
WACC9.59%
ROIC/WACC5.28
Cap/Depr(3y)163.83%
Cap/Depr(5y)132.28%
Cap/Sales(3y)2.67%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)459.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%156.25%
EPS Next Y25.28%
EPS Next 2Y17.02%
EPS Next 3Y13.27%
EPS Next 5Y-3.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.13%
Revenue Next Year-2.63%
Revenue Next 2Y1.23%
Revenue Next 3Y2.83%
Revenue Next 5Y0.79%
EBIT growth 1Y8.24%
EBIT growth 3Y11.69%
EBIT growth 5Y7.28%
EBIT Next Year1051.87%
EBIT Next 3Y148.64%
EBIT Next 5Y64.69%
FCF growth 1Y236.36%
FCF growth 3Y-74.97%
FCF growth 5Y-48.94%
OCF growth 1Y446.15%
OCF growth 3Y-53.28%
OCF growth 5Y-24.93%

INDIVIOR PHARMACEUTICALS INC / INDV Fundamental Analysis FAQ

What is the fundamental rating for INDV stock?

ChartMill assigns a fundamental rating of 5 / 10 to INDV.


What is the valuation status for INDV stock?

ChartMill assigns a valuation rating of 8 / 10 to INDIVIOR PHARMACEUTICALS INC (INDV). This can be considered as Undervalued.


How profitable is INDIVIOR PHARMACEUTICALS INC (INDV) stock?

INDIVIOR PHARMACEUTICALS INC (INDV) has a profitability rating of 7 / 10.


Can you provide the financial health for INDV stock?

The financial health rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 4 / 10.


What is the expected EPS growth for INDIVIOR PHARMACEUTICALS INC (INDV) stock?

The Earnings per Share (EPS) of INDIVIOR PHARMACEUTICALS INC (INDV) is expected to grow by 25.28% in the next year.